The reiteration of a Sector Perform rating and maintenance of the $4 price target by RBC Capital suggests a neutral outlook for bluebird bio. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's view. Therefore, the short-term impact on the stock price is likely to be neutral.